TY  - JOUR
AU  - Altomare, Daniele
AU  - Collij, Lyduine
AU  - Caprioglio, Camilla
AU  - Scheltens, Philip
AU  - van Berckel, Bart N. M.
AU  - Alves, Isadora Lopes
AU  - Berkhof, Johannes
AU  - de Gier, Yvonne
AU  - Garibotto, Valentina
AU  - Moro, Christian
AU  - Poitrine, Léa
AU  - Delrieu, Julien
AU  - Payoux, Pierre
AU  - Saint-Aubert, Laure
AU  - Molinuevo, José Luis
AU  - Grau-Rivera, Oriol
AU  - Gispert, Juan-Domingo
AU  - Minguillón, Carolina
AU  - Fauria, Karine
AU  - Sanchez, Marta Felez
AU  - Rădoi, Andreea
AU  - Drzezga, Alexander
AU  - Jessen, Frank
AU  - Escher, Claus
AU  - Zeyen, Philip
AU  - Nordberg, Agneta
AU  - Savitcheva, Irina
AU  - Jelic, Vesna
AU  - Walker, Zuzana
AU  - Lee, Ho-Yun
AU  - Lee, Lean
AU  - Demonet, Jean-François
AU  - Plaza Wuthrich, Sonia
AU  - Gismondi, Rossella
AU  - Farrar, Gill
AU  - Barkhof, Frederik
AU  - Stephens, Andrew W.
AU  - Frisoni, Giovanni B.
AU  - Consortium, AMYPAD
TI  - Description of a European memory clinic cohort undergoing amyloid‐PET: The AMYPAD Diagnostic and Patient Management Study
JO  - Alzheimer's and dementia
VL  - 19
IS  - 3
SN  - 1552-5260
CY  - Hoboken, NJ
PB  - Wiley
M1  - FZJ-2023-00157
SP  - 844-856
PY  - 2023
AB  - Introduction: AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility and cost-effectiveness of amyloid-PET in Europe. Here we present participants' baseline features and discuss the representativeness of the cohort.Methods: Participants with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI), or dementia were recruited in eight European memory clinics from April 16, 2018, to October 30, 2020, and randomized into three arms: ARM1, early amyloid-PET; ARM2, late amyloid-PET; and ARM3, free-choice.Results: A total of 840 participants (244 SCD+, 341 MCI, and 255 dementia) were enrolled. Sociodemographic/clinical features did not differ significantly among recruiting memory clinics or with previously reported cohorts. The randomization assigned 35% of participants to ARM1, 32% to ARM2, and 33% to ARM3; cognitive stages were distributed equally across the arms.Discussion: The features of AMYPAD-DPMS participants are as expected for a memory clinic population. This ensures the generalizability of future study results.Keywords: Alzheimer's; PET; amyloid; dementia; memory clinic population; mild cognitive impairment; subjective cognitive decline.
LB  - PUB:(DE-HGF)16
C6  - 35715930
UR  - <Go to ISI:>//WOS:000812481000001
DO  - DOI:10.1002/alz.12696
UR  - https://juser.fz-juelich.de/record/916865
ER  -